News

AbstractPurpose of ReviewCardiac amyloidosis (CA) results from myocardial infiltration by misfolded amyloidogenic proteins and represents a heterogeneous group of…

Join us March 13-15, 2026, for the virtual Masterclass in Cardiac Amyloidosis: Disease Spectrum, Diagnosis and Management.Led by Program Chair, Saurabh Malhotra, MD…

A certain blood protein regarded as an early indicator of Alzheimer's disease also appears to play a role in other disorders. Researchers at DZNE and the Hertie…

“It took almost three years to get a proper diagnosis,” said Scott, a retired firefighter and paramedic who has hereditary transthyretin amyloidosis (hATTR). It is…

ATTRACTnet was developed as an AI-based screening tool for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). In a real-world population, use of the…

Hereditary transthyretin‐mediated amyloidosis (hATTR) is a disorder that affects several body systems and can result in life‐threatening conditions like…

The US Food and Drug Administration (FDA) has released the clinical hold on a second trial evaluating Intellia Therapeutics’ transthyretin amyloidosis with…

CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing…

Cardiomyopathy associated with wild-type or hereditary transthyretin amyloidosis (ATTR-CM) is a serious, progressive, and ultimately fatal disease.3,4 There is…

Despite advances in noninvasive diagnostic techniques, patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in the Czech Republic still experience…